Expression of pro-apoptotic bid and bik genes is decreased in chronic myeloid leukemia and low levels of bik MRNA are associated with lack of response to imatinib treatment (2007)
- Authors:
- USP affiliated authors: CASTRO, FABÍOLA ATTIÉ DE - FCFRP ; MOREIRA FILHO, CARLOS ALBERTO - ICB ; MENDES, JOAO GUSTAVO PESSINI AMARANTE - ICB
- Unidades: FCFRP; ICB
- Subjects: LEUCEMIA; IMUNOLOGIA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Haematologica
- ISSN: 0390-6078
- Volume/Número/Paginação/Ano: v. 92, suppl. 1, p. 197, res. 0528, 2007
- Conference titles: Congress of The European Hematology Association
-
ABNT
CASTRO, Fabíola Attié de et al. Expression of pro-apoptotic bid and bik genes is decreased in chronic myeloid leukemia and low levels of bik MRNA are associated with lack of response to imatinib treatment. Haematologica. Pavia: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 23 abr. 2024. , 2007 -
APA
Castro, F. A. de, Ferreira, A., Zanichelli, M. A., Colassantti, M. D., Tobo, P. R., Lopes, L. R., et al. (2007). Expression of pro-apoptotic bid and bik genes is decreased in chronic myeloid leukemia and low levels of bik MRNA are associated with lack of response to imatinib treatment. Haematologica. Pavia: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. -
NLM
Castro FA de, Ferreira A, Zanichelli MA, Colassantti MD, Tobo PR, Lopes LR, Hamerschlak N, Moreira-Filho CA, Amarante-Mendes JGP, Jacysyn JF. Expression of pro-apoptotic bid and bik genes is decreased in chronic myeloid leukemia and low levels of bik MRNA are associated with lack of response to imatinib treatment. Haematologica. 2007 ; 92 197.[citado 2024 abr. 23 ] -
Vancouver
Castro FA de, Ferreira A, Zanichelli MA, Colassantti MD, Tobo PR, Lopes LR, Hamerschlak N, Moreira-Filho CA, Amarante-Mendes JGP, Jacysyn JF. Expression of pro-apoptotic bid and bik genes is decreased in chronic myeloid leukemia and low levels of bik MRNA are associated with lack of response to imatinib treatment. Haematologica. 2007 ; 92 197.[citado 2024 abr. 23 ] - Indoleamine 2,3-dioxygenase expression in chronic myelogenous leukemia patients: association with disease progression
- Down regulation of Hematopoietic SH2 domain containing (HSH2D) in the progression of the chronic myelogenous leukemia
- Correlation between metabolic alterations and apoptosis resistance confered by BCR-ABL expression
- Genomic approach to understand the mechanisms invilved in Bcr-Abl-mediated resistance to apoptosis
- Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide
- Development and characterization of murine models of T lymphoma to investigate the impact of oncogene expression
- Cosmomycin D, an anthracycline more potent than Doxorubicin for induction of tumor cell death, synergize with imatinib mesilate to induce apoptosis in Bcr-Abl-positive cells
- T lymphoma murine models to study the impact of ectopic expression of anti-apoptotic oncogenes
- BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia
- Study of pro and anti-apoptotic genes to understand the resistance of apoptosis mediated by Bcr-Abl
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
